Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
Phase: PHASE1
Conditions: B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 1 of 31 
 
 
IDELALISIB POST ALLOGENEIC HEMATOPOIETIC STEM CELL 
TRANSPLANT (HSCT)  IN B CELL DERIVED MALIGNANCIES: 
A PHASE 1 DOUBLE BLINDED RANDOMIZED PLACEBO 
TOXICITY TRIAL
 
Principal Investigator:  
 
 
 
 
 
Douglas E. Gladstone, MD 
Associate Professor of Oncology 
CRB I, Room 287 
1650 Orleans Street 
Baltimore, MD 21287 
dgladst1@jhmi.edu  
 
 
Co-Investigators: 
Javier Bolanos Meade, MD 
Richard Jones, MD 
Richard Ambinder. MD 
Lode Swinnen, MD 
 
Statisticians: 
Marianna Zahurak 
 
Study Site: 
 
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 
 
IRB Number: 
IRB00157704 
 
IND: 
131805 
Version Date: 
February 3, 2020  
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 2 of 31 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 3 of 31 
CONTENTS 
1. 
Introduction................................................................................................................................... 5 
1.1. 
Hypothesis ..................................................................................................................................... 6 
2. 
Objectives ...................................................................................................................................... 6 
2.1. 
Primary Endpoint ........................................................................................................................... 6 
2.2. 
Secondary Endpoint ...................................................................................................................... 6 
2.3. 
Tertiary Endpoints ......................................................................................................................... 6 
3. 
Inclusion/Exclusion Criteria ........................................................................................................... 6 
3.1. 
Inclusion Criteria ........................................................................................................................... 6 
3.2. 
Exclusion Criteria ........................................................................................................................... 7 
3.3. 
Enrollment ..................................................................................................................................... 7 
4. 
Study Procedures .......................................................................................................................... 7 
4.1. 
Premature Discontinuation of Study Therapy ............................................................................... 7 
4.2. 
Premature Termination of a participant from the study .............................................................. 8 
4.3. 
Table 1.  Schedule of Assessments ................................................................................................ 9 
5. 
Known Toxicities and Dose Adjustments ...................................................................................... 9 
5.1. 
Known toxicities of idelalisib ......................................................................................................... 9 
5.2. 
Dose adjustment of Idelalisib ...................................................................................................... 11 
Pneumonitis .............................................................................................................................................. 11 
Hepatotoxicity ........................................................................................................................................... 11 
Diarrhea..................................................................................................................................................... 11 
Neutropenia and thrombocytopenia ........................................................................................................ 12 
Late Onset Neutropenia (LON) .................................................................................................................. 12 
6. 
Study Statistics ............................................................................................................................ 12 
7. 
Correlative Studies ...................................................................................................................... 15 
7.1 
Rationale and outline of correlative studies ............................................................................... 15 
7.2  
Analysis of Correlative Endpoints…………………………………………………..…………………………………..…..23 
7.3 
OPERATING PROCEDURES FOR SPECIMEN COLLECTION.......................................................................... 16 
8. 
Risks ............................................................................................................................................. 19 
8.1. 
IDELALISIB RISKS ............................................................................................................................. 19 
8.2. 
RISK MINIMIZATION ....................................................................................................................... 19 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 4 of 31 
9. 
Adverse Events….. ................................................................................................................... ..  20 
9.1. 
Overview ..................................................................................................................................... 20 
9.2. 
Definitions ................................................................................................................................... 20 
9.3. 
Collecting and Recording Adverse Events ................................................................................... 21 
9.4. 
Grading and Attribution of Adverse Events ................................................................................ 22 
Attribution Definitions .......................................................................................................................... 22 
9.5. 
Reporting Serious Adverse Events .............................................................................................. 23 
10. 
Ethical, regulatory, and administrative considerations .............................................................. 23 
10.1. 
Statement of Compliance ............................................................................................................ 23 
10.2. 
Informed Consent........................................................................................................................ 23 
10.3. 
Privacy and Confidentiality .......................................................................................................... 24 
10.4. 
INSTITUTIONAL REVIEW .............................................................................................................. 24 
10.5. 
Monitoring plan ........................................................................................................................... 24 
11. 
References ................................................................................................................................... 24 
12. 
Appendix 1-4 ............................................................................................................................... 27 
12.1. 
Study Calendar…………………………………………………………………………………………………………………..……28 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 5 of 31 
1. INTRODUCTION 
For all relapsed B cell derived hematologic malignancies, allogeneic bone marrow transplantation (allo BMT) 
is often the most definitive curative intent therapy.   Historically, there have been four obstacles decreasing 
overall survival (OS) associated with allo BMT:  preparative conditioning toxicity, donor availability, graft-versus-
host-disease (GVHD) and disease relapse.   Reduced intensity conditioning (RIC) regimens have dramatically 
reduced alloBMT toxicity and have expanded the use of this therapy to patients up to 75 years of age.(1-3)  The 
use of alternative donors has resulted in an average of 2.7 donors for each patient in Johns Hopkins 
University.(4)  The use of post-transplant cyclophosphamide has reduced the incidence of Grade III-IV GVHD to 
6% - 11%.(5-7) However, disease relapse after successful engraftment during allo BMT remains the limiting 
factor for improving overall survival. (5, 6, 8) 
Currently, in order to improve OS, the BMT program at JHH has recently focused on the introduction of anti-
neoplastic therapy post transplantation.  We use the allo HSCT as a platform to allow a new intolerant immune 
system to interact with a post allo HSCT biologic or therapeutic intervention.  Currently, to improve overall 
survival, the focus of the BMT program at JHH the introduction of anti-neoplastic therapy post transplantation: 
where the allo BMT serves as a platform to allowing a new intolerant immune system to interact with the post 
allo BMT intervention.   The importance of post BMT therapy has been made evident with tyrosine kinase 
inhibition (TKI) in Ph+ ALL and Ph+ CML, where patients who had disease progression while on TKI therapy pre-
allo BMT enjoy marked improvement in OS when TKI is part of a maintenance program (9-12); the use of DNA 
hypomethylation agents after allo BMT for relapsed myeloid malignances (13); or the use of rituximab after allo 
BMT in follicular lymphoma (PMID 26183076).    At JHH we are currently, utilizing post allo BMT: TKI in Ph+ 
leukemia’s, sorafenib and other multi-kinase inhibitors in FLT3-ITD AML, and 5-azacytidine in MDS patients.   
Previous experience with Idelalisib, an orally-administered, selective inhibitor of Phosphoinositide 3 kinase 
(PI3K)- is extremely effective in inducing partial responses to complete responses in many B-cell derived 
malignancies.  Considering this published track record, idelalisib should be studied in the post allo BMT setting.  
While evaluating patients using a pre-transplant conditioning approach in patients with high risk CLL based on 
cytogenetics, would also be of interest, recent NCCN recommendations list idelalisib as the treatment option in 
this cohort, hence our focus on post-transplant maintenance.  Moreover, a non-disease specific but treatment 
oriented selection of patients will likely reveal a clinically significant endpoint signal more quickly.   However, 
before embarking on a large randomized trial to determine the impact Idelalisib has on the relapse-free survival 
after allo BMT for B cell derived hematologic malignances, a phase 1 toxicity/safety trial is warranted.   
Here at JHH we have one of the world’s largest experiences with alloHSCT.  We propose a double blinded 
randomized phase I placebo trial where all patients who have undergone alloHSCT for a B-cell derived 
hematologic malignancy be offered either idelalisib 100mg or placebo twice daily for 180 days starting 
approximately 90 days after their HSCT.   
While Idelalisib is a selective PI3K inhibitor, most affecting the p110
isoform, the expression of PI3K on 
regulatory NK cells requires careful clinical study. (14)    In fact, PI (3) K
blockade can affect suppressor Treg 
function which could alter the incidence of GVHD in this population. (15) In addition, literature data has shown 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 6 of 31 
targets upstream of PI3K, i.e. Syk, also show evidence of B cell modulation in the transplant setting (Allen et al., 
2014)  
 
1.1. 
HYPOTHESIS 
Idelalisib can be safely used as maintenance therapy after allo HSCT in patients with B cell derived 
hematologic malignances.   
 
2. OBJECTIVES 
2.1. 
PRIMARY ENDPOINT 
To evaluate the safety of idelalisib, as post alloHSCT maintenance therapy in patients with B-cell 
hematologic malignancies, by comparing to placebo.  
2.2. 
SECONDARY ENDPOINT 
Event free survival at one year 
2.3. 
TERTIARY ENDPOINTS 
To explore the association between potential biomarkers, clinical activity and/or toxicity of Idelalisib 
administered after allogeneic BMT. Multi-color flow cytometric analyses of immune markers pre- and post-
treatment, high-throughput DNA sequencing of rearranged TCRβ CDR3 regions from T cell genomic DNA, 
cytokine measurements, and immunohistochemistry is planned. In addition, we may perform exploratory gene 
expression analysis of immune biomarkers in the bone marrow aspirates and whole or targeted exome 
sequencing of the lymphoma cells.  
3. INCLUSION/EXCLUSION CRITERIA 
3.1. 
INCLUSION CRITERIA 
1. >18 years of age  
2. Patients having undergone alloHSCT to treat a B-cell derived hematologic malignancy: accepted 
alloHSCT regimens include: myeloablative or reduced intensity conditioning from any donor (matched, 
partially mismatched or cord) and any source (peripheral blood, bone marrow, or cord). 
3. T bili ≤ 1.5 mg/dL except for patients with Gilbert’s syndrome or hemolysis 
4. AST, ALT and alk phos all < 2.5X ULN  
5. Karnofsky performance score ≥ 40 
6. ECOG ≤3 
7. For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 
50 mIU/m within 72 hours before the start of study medication.  
8. Use of two forms of contraception with less than a 5% failure rate or abstinence by all transplanted 
patients for a minimum of 1 month after the last dose of Idelalisib. For the first 60 days post-transplant, 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 7 of 31 
transplant recipients should be encouraged to use non-hormonal contraceptives due to the potential 
adverse effect of hormones on bone marrow engraftment. 
9. Ability to receive oral medication. 
10. Ability to understand and provide informed consent. 
3.2. 
EXCLUSION CRITERIA 
1. 
ECOG >3 (Karnofsky <40%) 
2. 
ALT,  AST >2.5 ULN or total bilirubin >1.5 ULN (not attributable to Gilbert’s) 
3. 
Women who are pregnant or breastfeeding.  
4. 
Exclude if patient has cirrhosis or is currently being actively treated for hepatitis C.  
5. 
History of positive HIV-1 or HIV-2 serologies or nucleic acid test. 
6. 
Active hepatitis B infection as documented by positive Hepatitis B PCR assay 
7. 
Use of investigational drug, other than the study medications specified by the protocol, within 30 days 
of transplantation. 
8. 
Receipt of a live vaccine within 30 days of receipt of study therapy. 
9. 
> Grade II aGVHD 
10. The presence of any medical condition that the Investigator deems incompatible with participation in 
the trial 
11. Subjects who are required to use a medication classified as a strong CYP3A inducer of inhibitor. An 
exception can be made for those patients required to take azole based antifungal prophylaxis and/or 
treatment.   
3.3. 
ENROLLMENT 
Approximately 60 patients who have undergone allo BMT for B-cell derived hematologic malignancies.   
4. STUDY PROCEDURES 
 
Idelalisib, 100mg twice daily, starting day +90 (+-/ 10 days) and at least five days after the 
discontinuation of filgrastim, if ANC greater than 1000 and PLT 50>Gi/L and continued through day +270.  
Patients will have a CBC with platelet count and comprehensive metabolic panels performed every 14 
days beginning at day +90 through day +120, then monthly through day +270.   
Patients will be monitored for treatment-limiting toxicities defined as Idelalisib interruption for >14 days, or 
any other Grade 3 or higher adverse events as defined by CTCAE IV not captured in the protocol for dose de-
escalation.   All Adverse events will be collected and assessed for causality but only AEs Grade 2 and higher will 
be recorded on the Master AE log. Patient’s idelalisib will be dose adjusted for the expected toxicities of idelalisib 
including pneumonitis, hepatitis, neutropenia, thrombocytopenia and loose stools.   
4.1. 
PREMATURE DISCONTINUATION OF STUDY THERAPY 
Study therapy is defined as initiation of any study-mandated therapies and study procedures described in 
section 4.0.  
Study therapy will be discontinued for the following reasons: 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 8 of 31 
 
Adverse experience. If a participant suffers from an adverse experience that, in the judgment of the 
Principal Investigator, may present an unacceptable consequence or risk to the participant. 
 
Intercurrent illness or infection. If during the course of the study a participant develops an illness or 
infection that is not associated with the condition under study and that requires treatment not 
consistent with protocol requirements; or, if a participant develops an intercurrent illness that in the 
judgment of the Principal Investigator justifies discontinuation. 
 
Protocol violation. If a participant cannot comply with the study protocol and the protocol 
deviations are sufficient to jeopardize his or her well-being or the integrity of the study. 
 
Pregnancy. 
 
Investigator discretion. If the Investigator determines that the study therapy is no longer in the best 
interests of the participant.  
 
If the participant is unwilling or unable to continue on study therapy. 
4.2. 
PREMATURE TERMINATION OF A PARTICIPANT FROM THE STUDY 
Participants will be prematurely terminated from the study for the following reasons: 
 
Withdrawal of consent.  If for any reason a participant withdraws consent during the study they will 
be terminated from the study. All information and biospecimens collected from the participant prior 
to their withdrawal of consent will continue to be utilized by the study. 
 
Failure to return.  Participants who do not return for visits and who do not respond to repeated 
attempts by the site staff to have them return will be considered lost to follow-up.   
 
 
 
 
 
 
 
 
 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 9 of 31 
4.3. TABLE 1.  SCHEDULE OF ASSESSMENTS 
 
Screening and 
Baseline  
( 
Cycle 1, Day 1 
Day +90 (± 10 
Days) 
) 
Cycle 1, Day 15 
 (± 7 Days) 
Cycles 2-6, Day 1 
30 days Post 
last dose 
Month 12 
(± 14 Days) 
Informed 
Consenta 
Days 60 -100 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
Physical Exam 
X 
X 
 
X 
X 
X 
AE Assessment 
X 
X 
 
X 
X 
X 
CBC with diff  
X 
X 
X 
X 
X 
X 
Comprehensive 
metabolic panel e 
(CMP) b 
Xb 
Xb 
Xb 
Xb 
Xb 
Xb 
PT, PTT, INR 
X 
 
 
 
 
 
Serum 
-HCG 
(if applicable) 
X 
 
 
 
 
 
CMV PCRd 
Xd 
X 
X 
X 
 
 
Dispense 
Idelalisib 
 
X 
 
X 
 
 
Standard of care 
per institution 
 
 
 
 
 
 
T-cell chimerism 
X 
 
 
 
 
X 
Bone marrow 
biopsy (as std of 
care) 
X 
 
 
 
 
X 
aGVHD/cGVHD 
assessments 
X 
X 
X 
X 
 
X 
Correlative 
studiesc, 
X 
X 
 
Xc 
 
X 
 
 
 
 
 
 
 
aInformed consent will be collected beginning on Day +60 after BMT until Day +100. 
b CMP to include BUN, creatinine, sodium, potassium, chloride, AST, ALT, total bilirubin, alkaline phosphatase.  
c Additionally specimens should be obtained from peripheral blood and bone marrow collections as a part of routine 
clinical care such as GVHD, toxicity and/or disease relapse Correlative peripheral blood samples should be collected on 
Day 1 of every other cycle beginning with Cycle 2 
dCytomegalovirus (CMV) viral load assay will be monitored by PCR every 14 days between days +90-and day +120, then 
monthly through day +270: treat according to BMT policy guidelines.  
 
 
 
5. KNOWN TOXICITIES AND DOSE ADJUSTMENTS 
5.1. 
KNOWN TOXICITIES OF IDELALISIB 
Idelalisib is FDA approved for the treatment of relapsed chronic lymphocytic leukemia/small lymphocytic 
lymphoma and follicular B-cell non-Hodgkin lymphoma.  Idelalisib may cause:  

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 10 of 31 
 
ALT/AST elevations and hyperbilirubinemia (most frequently occurs within the first 12 weeks of 
treatment); incidence of serious hepatotoxicity: 14.0% 
 
Diarrhea (mean time to occurrence 7.2 months); incidence of serious/severe diarrhea: 14.0% 
 
Pneumonitis; incidence <5% 
 
Neutropenia: Grade 3 or 4 neutropenia occurs in approximately 31% of patients receiving the 150mg 
bid dose.   
 
Rash: Grade 3 or 4 rash occurred in approximately 21% of patients receiving the 150mg BID dose. 
 
CYP3A affects: CYP3A inducers can reduce the AUC of idelalisib by 75%; CYP3A inhibitors can 
increase the AUC of idelalisib by 1.8 fold; idelalisib is strong CYP3A inhibitor. A list of these drugs 
can be found in appendix 4.   Importantly, with direct relevance to this study is the lack of data 
supporting strong interaction with voriconazole.  Azoles are often the medication of choice for 
patients with suspect fungal or anti-bacterial non-responsive fevers during alloBMT.  The 
elimination of idelalisib is predominantly mediated by the hepatic pathway.  Idelalisib is primarily 
metabolized by aldehyde oxidase with a lesser involvement of cytochrome P450.  The major 
metabolite of idelalisib is GS-563117.  Data indicate that CYP3A inhibition by concurrent use of 
azoles may result in modestly higher exposures of idelalisib, but the change is not of clinical 
relevance21. In this study, as the dosing of idelalisib is already reduced to 100mg bid to provide 
additional risk mitigation.  Additionally, patient’s receiving azole therapy while on idelalisib will have 
serum levels monitored to adjust to target levels. 
Therefore, to protect patients in this study the following measures are employed: 
 
Patients will have comprehensive metabolic panels performed every 2 weeks through day +120, then 
monthly through day +270.  
 
Patients post alloBMT may develop intestinal aGVHD which may present with diarrhea or ileus.  All 
patients with >3 grade diarrhea will also be evaluated for aGVHD in addition to idelalisib dose 
modification. 
 
Patients post alloBMT may develop aGVHD which often presents with a generalized cutaneous rash. All 
patients with >3 grade rash will also be evaluated for aGVHD in addition to potential idelalisib dose 
modification.  
 
Patients post alloBMT often develop late neutropenia after achieving neutrophil recovery.  To help limit 
the depth of neutropenia that could be attributable idelalisib, idelalisib will be dosed at 100mg bid, the 
suggested dose reduction for patients experiencing an ANC <.5Gi/L while on the standard 150mg bid 
dosing schedule 
 
CYP3A interactions. Commonly, patients post alloBMT require azole based antifungal prophylaxis 
and/or treatment.  Patients receiving posaconazole or voriconazole will have these levels checked every 
14 days while receiving idelalisib.  
 
Additionally, in the post alloBMT patient population, novel toxicities need to be considered, therefore, 
stopping rules will be established to stop this study, if compared to the placebo control the incidence of 
GVHD or any other toxicity caused by idelalisib or placebo causes discontinuation at a rate differential 
of >10%.   

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 11 of 31 
5.2. 
DOSE ADJUSTMENT OF IDELALISIB OR PLACEBO 
Study drug consists of oral idelalisib or placebo tablets. The standard dose of idelalisib for this protocol is 
100mg idelalisib tablets (orange, oval shaped and film coated) or matched 100mg silicified microcrystalline 
cellulose placebo tablets taken twice a day.  
When necessary,  idelalisib or matched placebo dose can be adjusted to  100 mg taken once a day. Based 
on current PK data supplied by Gilead, a clinical trial examining various idelalisib doses in combination with a 
second drug held at a fixed dose found that  the steady state AUC for idelalisib 100 mg QD dosing reduced 
patient idelalisib exposure by ~30% as compared to 50 mg BID dosing. The investigators further determined that 
the second drug did not influence the idelalisib drug concentrations at the studied doses. Additionally, Gilead 
study 101-02 demonstrated AUC0–24h were similar, 19,600 and 16,300 ng.h/mL for 150mg BID and 300mg QD, 
respectively.21 Due to this data, we are confident that a dose reduction from 100mg BID to  100mg tablets taken 
once daily will sufficiently reduce patient exposure to idelalisib in the context of this study.  
PNEUMONITIS 
Non-infectious pneumonitis can occur with Idelalisib use and occurs in allogeneic bone marrow transplant 
recipients. A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-
specific respiratory signs and symptoms such as hypoxia, pleural effusion, cough or dyspnea, and in whom 
infectious, neoplastic and other non-medicinal causes have been excluded by means of appropriate 
investigations. Opportunistic infections such as PJP should be ruled out in the differential diagnosis of non-
infectious pneumonitis. Patients should be advised to report promptly any new or worsening respiratory 
symptoms.  
If idiopathic, symptomatic pneumonitis occurs, stop study drug until symptoms resolve to less than or equal 
to grade 1. The use of corticosteroids may be indicated. Study drug may be reintroduced at a dose of 100 mg 
once daily.  If idiopathic pneumonitis recurs at the reduced dosing level, then discontinue study drug 
permanently.   
HEPATOTOXICITY 
Transaminitis and hyperbilirubinemia can occur with idelalisib use and are also common in allogeneic bone 
marrow transplant recipients.  For patients experiencing an AST/ALT or bilirubin >5x ULN that is unexplained by 
other factors, hold study drug until the parameter is < 2ULN and restart at 100mg once daily.  If the parameter 
should rise again >5 ULN, discontinue study drug.  For AST/ALT >20x ULN (or Bilirubin >10x ULN), regardless of 
attribution, study drug should be permanently stopped.  
DIARRHEA 
Diarrhea can occur with idelalisib use and is also common in allogeneic bone marrow transplant recipients.  
Prior to major pharmacologic intervention, common infectious causes of loose stooling should be evaluated.  
For loose stools, in the absence of major infections, anti-motility agents may be offered and/or light steroid 
preparations.  For patients with significant stooling, >1L daily, hold study drug and consider colonic biopsy if 
there is evidence to suggest aGVHD.   Once stooling is <0.5L day, restart at 100mg oncedaily.  If stooling should 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 12 of 31 
again increase to >1L daily, discontinue study drug.  For life-threatening diarrhea, study drug should be 
permanently stopped.  
 
NEUTROPENIA AND THROMBOCYTOPENIA 
Neutropenia and thrombocytopenia can occur with idelalisib use and are also common in allogeneic bone 
marrow transplant recipients.    For ANC < 500 or PLT < 25,000, monitor CBC with differential weekly, hold study 
drug until ANC >1,000 and PLT count >50,000 and restart at the original dose. If a subject develops ANC < 500 
or PLT < 25,000 a second time, hold study drug until ANC >1,000 and PLT count >50,000 and restart at 100mg 
once daily.  If a subject who is on 100mg once daily develops ANC < 500 or PLT < 25,000, discontinue study drug. 
Acute GVHD: Patients with symptomatic aGVHD will be treated as per institutional guidelines.  If after seven 
days of therapy there is evidence of progressive aGVHD, study drug will be stopped for at least seven days.  If it 
is determined that study drug was not causative of the aGVHD it may be restarted at the discretion of the 
primary oncologist.  If after 14 days of active therapy there is no improvement of the aGVHD, study drug will be 
stopped for at least seven days.  If it is determined that study drug was not causative of the aGVHD persistence 
it may be restarted at the discretion of the primary oncologist.    
LATE ONSET NEUTROPENIA (LON)  
Rituximab- associated LON is defined by most investigators as grade III-IV neutropenia (ANC <500 cells/µL), 
occurring after the ANC has recovered to within normal limits, but within 3-4 weeks after the last dose of 
rituximab22 . If subject develops LON after rituximab use or which per medical judgement can be attributed to 
another cause outside of the use of idelalisib, the subject may receive the appropriate medical or surgical 
intervention without being taken off study or having study drug held. If, in the judgment of the attending 
physician, the subject has had no resolution of symptoms after receiving standard intervention, study drug  will 
be held until ANC >1000. 
 
6. STUDY STATISTICS 
This is a phase I study of Idelalisib, an orally-administered, selective inhibitor of Phosphoinositide 3 kinase 
(PI3K)-δ.  It has been successfully used pre-transplant to induce partial and complete responses in many B-cell 
derived malignancies.  In this study Idelalisib will be evaluated in the post-transplant setting.  Patients receiving 
a standard of care allogeneic hematopoietic stem cell transplant from any source: cord, marrow, or peripheral 
blood will be eligible.   Patients will be randomized in a 2:1 ratio to either 100 mg Idelalisib twice daily from day 
90 (±10 days) following transplant, Arm A, or a placebo, Arm B, and monitored for toxicity until day 270.  
Study treatment plan: Idelalisib day +90 [+/- 10 days), 100mg twice daily, and at least 5 days after the 
discontinuation of filgrastim if ANC is greater than 1,000 and PLT 50>Gi/L and <grade 2 aGVHD.  Patient’s 
Idelalisib will be dose adjusted for the expected toxicities of Idelalisib including pneumonitis, hepatitis, 
neutropenia, thrombocytopenia and loose stools.   
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 13 of 31 
Primary endpoint and design: The primary goal of this study is to evaluate the safety of Idelalisib as post-
transplantation maintenance in patients undergoing an allogeneic BMT.  In addition to the allowed dose 
reductions, a safety monitoring plan will be implemented to ensure that other treatment-limiting events are not 
elevated.  The study will be monitored between the date of randomization and day 270 post-transplant.  For 
safety monitoring, treatment-limiting toxicities will be defined as Idelalisib interruption for >14 days, or other 
grade 3 or higher adverse events as defined by CTCAE IV not captured in the protocol for dose de-escalation.  
The trial will assume that, a priori, the probability of these events in both arms of the study will follow a Beta 
(0.10, 0.90) prior distribution.  This distribution corresponds to an assumption that 10% of patients might 
experience a treatment-limiting toxicity. 
Sample size/accrual Rate:  The accrual rate for this study is expected to be 20 patients per year.  The total 
sample size will be 45 patients, 30 on the Idelalisib arm (Arm A) and 15 on the control arm (Arm B).  The safety 
objective of this trial is based on the precision of estimating the specified treatment-limiting toxicity events.  An 
approximation to the precision will be made using binomial confidence intervals.  Thirty patients on the Idelalisib 
arm will allow us to estimate the proportion of patients experiencing post-transplant events with a precision of 
± 0.19%.   
Interim analyses and operating characteristics:  For monitoring we will compute the posterior probability 
of a treatment-limiting toxicity between day 90 and 270  in each arm of the study, given the data and prior 
distribution, Beta(0.10, 0.90), and evaluate whether to hold accrual after fixed cohorts of patients.  Monitoring 
will occur in groups of 15 patients, beginning after the first 10 enrolled on Arm A.  The maximum sample size 
will be 45 patients, 30 in Arm A and 15 in Arm B.  The stopping rule will recommend a safety review if it becomes 
clear that the posterior probability of a treatment-limiting toxicity in Arm A exceeding Arm B by 0.10 is 75% or 
greater.  Operating characteristics of the study with Arm B treatment-limiting toxicity of either 5%, Table 1, or 
10%, Table 2, and varying toxicities in Arm A are based on 1,000 simulations of the trial. 
 
Table 1. Scenarios with control arm (Arm B) treatment-limiting toxicity of 5% 
Both arms prior: Beta (0.10, 0.90), assumes prior for toxicity is 10%, delta of 0.10, and 75% cutoff.  
 2:1 randomization Total N=45 
 
 
Delta=0.10 
Delta=0.10 
Scenario:  
Control, Idelalisib 
Stopped for toxicity 
Avg. sample size 
Control, Idelalisib 
1:  0.05,  0.05 
1.3% 
14.9, 29.8 
2:  0.05,  0.10 
6.8% 
14.4, 28.8 
3:  0.05,  0.15 
19.2% 
13.4, 26.8 
4:  0.05,  0.20 
32.4% 
12.3, 24.7 
5:  0.05,  0.25 
53.1% 
10.5, 21.0 
6:  0.05,  0.30 
68.2% 
9.3, 18.7 
7:  0.05,  0.35 
82.3% 
8.0, 16.0 
8:  0.05,  0.40 
89.8% 
7.1, 14.2 
9:  0.05,  0.45 
94.9% 
6.3, 12.6 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 14 of 31 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 
Scenarios with control arm (Arm B) treatment-limiting toxicity of 10% 
Both arms prior: Beta(0.10, 0.90), assumes prior for toxicity is 10%, delta of 0.10 and 75% cutoff. 
2:1 randomization Total N=45 
 
 
Delta=0.10 
Delta=0.10 
Scenario:  
Control, Idelalisib 
Stopped for toxicity 
Avg. sample size 
Control, 
Idelalisib 
1:  0.10,  0.10 
4.9% 
14.6, 29.1 
2:  0.10,  0.15 
12.0% 
13.9, 27.8 
3:  0.10,  0.20 
27.9% 
12.7, 25.4 
4:  0.10,  0.25 
44.3% 
11.4, 22.8 
5:  0.10,  0.30 
59.0% 
10.1, 20.2 
6:  0.10,  0.35 
70.7% 
9.3, 18.5 
7:  0.10,  0.40 
83.4% 
8.1, 16.1 
8:  0.10,  0.45 
90.0% 
7.3, 14.5 
9:  0.10,  0.50 
94.4% 
6.6, 13.1 
 
 
Secondary endpoint:  
1. Event-free survival at one year. 
 
Analysis Plans: 
Toxicities will be summarized descriptively by grade and type.  Cumulative incidences of aGVHD, relapse, and 
NRM will also be computed using Fine and Gray’s method for competing risks.  Treatment of 
relapse/progression, graft failure, and death are considered competing risks for GVHD; relapse/progression is a 
competing risk for NRM; and death before relapse/progression is a competing risk for relapse/progression. In 
addition, we plan to report aGVHD incidences with only graft failure and death regarded as competing risks. 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 15 of 31 
Using the Kaplan-Meier method, the probability of 1-year event-free survival will be estimated and reported 
with 95% confidence intervals.  The proportions of patients who are event-free at 1 year will also be estimated 
with a 95% exact binomial confidence interval.    
    
 
 
7. CORRELATIVE STUDIES  
7.1  RATIONALE AND OUTLINE OF CORRELATIVE STUDIES  
 
The overarching goals of our correlative studies are to: 
i) 
Characterize the effect of Idelalisib on allogeneic T and B cells, particularly on their re-distribution, in vivo 
expansion, activation, and effector differentiation after treatment 
ii) Identify potential predictive biomarker candidates to allow for better selection of patients after alloBMT 
who may benefit or whom are likely to have toxicity from Idelalisib therapy. 
iii) Characterize the mechanisms of relapse after Idelalisib such as B cell and T cell dysfunction.  
 
 
 
Hypothesis: We hypothesize that Idelalisib administration will have an effect on GVHD modulation. This 
prediction is based on the data suggesting that PI3K pathway is activated in activated/memory T cells 
responsible for autoimmunity (16). Interestingly, Ali et al., have recently shown that PI3K  inactivation 
results in the disruption of two tumor-associated immune-suppressive cell types- regulatory T cells and 
myeloid-derived suppressor cells (17). Thus, we also hypothesize that p110  inhibition with Idelalisib can 
enhance allogeneic antitumor immunity post-transplant that can be measured as increased TCR diversity 
and the emergence of unique TCR clonotypes. 
 
Flow Cytometry Studies: We will perform multi-color flow cytometry on peripheral blood (PB) and bone 
marrow (BM) specimens before and after Idelalisib treatment using three pre-determined panels of mAbs 
including but not limited to those specific for CD3, CD4, CD8, PD-1, CD45RA, CCR7, CD25, CD27, CD28, CD69, Ki-
67, T-bet, CD127, FoxP3, HLA-DR, CTLA-4, TNFRII, TIM3, LAG-3, CD160, 2B4, BTLA, KLRG-1, CD16, and CD56. This 
multi-color approach allows examination of different CD4+ and CD8+ T cell subpopulations (expressing CD45RA, 
CCR7, CD27, and CD28), phenotypic separation of human CD4+FoxP3+ T cells into three distinct subpopulations 
as well as assessment of their proliferative status (% Ki-67 positive cells). (18) The expression of CD69, HLA-DR 
and TNFRII will be measured to characterize T cells activation status and the expression of co-inhibitory 
molecules (PD-1, TIM3, LAG-3, CD160, 2B4, BTLA, KLRG-1) will be studied. Natural killer cells (NK), NK-T cells will 
be enumerated using CD16 and CD56 (NK/NK-T cells). Additionally effects of Idelalisib on myeloid-derived 
suppressor cells and B cell depletion post-transplant will be assessed. As a part of PBMCs collection and 
mononuclear cell isolation we will also collect plasma that will be stored and used for measurement of defined 
cytokines (IL-2, IL-6, IL-10, IFN-γ,TNF-α) to assess Idelalisib -induced global T cell activation or for proteomic 
analysis of defined molecules associated with GVHD (proteomic studies on PTCy-based platforms are being 
prepared for publication (20)).  
Molecular studies: Immune Profiling of T cell Repertoire: The studies proposed will evaluate the T cell 
receptor (TCR) diversity in T cells isolated from PB and BM from patients before and after treatment with 
Idelalisib on the parent clinical trial. We will determine TCR diversity and clonal composition using a molecular 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 16 of 31 
and computational approach based on high-throughput DNA sequencing of rearranged TCRβ CDR3 regions from 
T cell genomic DNA. This approach allows direct measurement of the TCRβ CDR3 region sequence diversity in 
any arbitrarily complex population of T cells, and also permits quantitative description of the clonal composition 
of the population. (19) The Luznik laboratory in collaboration with the E. Warren laboratory from Fred 
Hutchinson Cancer Research Center (FHCRC) have performed extensive monitoring and tracking of the TCR 
repertoires in patients undergoing alloHSCT (manuscript in preparation). We are utilizing an established 
multiplex PCR strategy to amplify the CDR3 region of the TCR, spanning the variable region formed by the 
junction of the V, D and J segments and their associated non-template insertions followed by Illumina-based 
sequencing methodology, an well-characterized methodology developed by Adaptive Technology 
(http://www.adaptivebiotech.com/technology/). Sequencing is followed by comprehensive bioinformatics 
analyses focused on determining the diversity of the T cell and B cell repertoires as well as the entropy and 
clonality of each repertoire consistent with previous studies. Through these ongoing studies we have developed 
substantial experience not only in using and analyzing DNA retrieved from unsorted PBMCs but also from sorted 
T cells subpopulations (naïve vs memory vs regulatory), paired PB and BM samples and as well from DNA 
retrieved from FFPE archived tissues.  
The long-term goal of this correlative work is to uncover biomarkers that in future may predict better 
integration of Idelalisib post-transplant. This correlative work will also provide deeper insight into the, effects 
of Idelalisib on GVHD and allogeneic anti-tumor immunity as well as on the mechanisms of failure to eradicate 
B cell malignancies after Idelalisib treatment. 
7.2  
Analysis of Correlative Endpoints 
The analyses of pre- and post-treatment PB and BM specimens for immune parameters will be descriptive 
and graphical in nature.  Data will be summarized for each cohort separately.  The change in flow values at each 
time point after Idealisib relative to the baseline value will be will checked for skewness and log-transformed as 
appropriate.  The changes will be modeled using mixed-effects, linear regression models that included fixed 
effects for time and a random effect for the patient to account for within-patient correlation of measurements.  
To explore potential differences in the change in flow values across patient subgroups, interaction terms will be 
included in the regression models.  Post-treatment changes in gene expression in immune gene signaling circuits 
in tumor biopsies and PB will be summarized with descriptive statistics and correlated with clinical outcomes. 
 
7.3 
OPERATING PROCEDURES FOR SPECIMEN COLLECTION 
Peripheral blood and bone marrow specimen collection will be performed as delineated in the Table 1 
Schedule of Assessment Section 4.3 and additionally at the times when peripheral blood and bone marrow 
collections are performed for clinical care such as GVHD, toxicity and/or disease relapse. 
Bone marrow: 4 x 8mL will be collected in green top sodium heparin tubes (~20-30 mL). Re-adjustment of 
the direction of bone marrow aspirate needle should take a place after each 10 cc is collected to prevent 
hemodilution. At the time of collection, green top tubes must be thoroughly mixed to prevent clotting. 
Peripheral blood: 5x8mL  green top sodium heparin tubes of blood (~40mLs) will be collected at each time 
point. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 17 of 31 
Specimens should be labeled with the patient’s study number (given at the time of registration), study 
number, sample collection date and time, and sample source (PB or BM). Sample collection date and time, and 
sample source (PB or BM) will be recorded on correlative collection worksheet and copy included with delivery. 
All data should be kept in laboratory log. At each sampling time, BM and PB mononuclear cells (PBMC) will be 
processed via Ficoll density gradient centrifugation. The washed cells will be counted, triaged for DNA isolation, 
and viably cryopreserved using a controlled-rate freezer with transfer to the vapor phase of liquid nitrogen for 
long-term storage (Luznik laboratory). 
 
The Sidney Kimmel Comprehensive Cancer Center (SKCCC) specimens should be delivered to the Luznik 
laboratory immediately after collection.  
 
Specimen collection / processing: PB and BM specimens should be collected as outlined in the Trial Flow 
Chart 6.0.  
 
7.3 FREEZING PROTOCOL (SOP) 
1. Prepare 50mL falcon tubes with Ficoll density grade media (Histopaque) 
 
Ratio Ficoll : blood should be 1:1 
 
Do not exceed 20mL Ficoll to 20mL blood (i.e. total volume of 40mL) 
 
2. Slowly layer blood on top of Ficoll 
 
Use whole blood or marrow aspirate, do not dilute with PBS or anything else 
 
Be careful not to mix the two layers 
 
3. Centrifuge: spin at the following settings: 
 
1240rpm (=364G) 
 
20 Celsius 
 
Break off 
 
30min 
 
4. Prepare 6 small Eppendorf tubes 
 
Take off 6 x 500ul of plasma (top layer; blood only; not for BM aspirate) and put it into Eppendorf 
tubes 
 
Be careful not to get into any layer but the plasma layer 
 
Long term storage in -80 Celsius freezer 
 
5. Soak up PBMC layer with transferring pipette and put it into a new 50mL Falcon tube 
 
Fill up with PBS up to 45mL, vortex 
 
Centrifuge: Spin at 1240 rpm (=364G), 4 Celsius, break high, for 5 minutes 
 
6. First wash 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 18 of 31 
 
Dump supernatant 
 
In case of visible RBC contamination add 1Ml of lysing buffer to the cell pellet, vortex, and leave 
for 1 minute. Then add 20mL of PBS 
 
If there is no RBC contamination only add 20mL of PBS and vortex 
 
Centrifuge: Spin at 1240 rpm (=364G), 4 Celsius, break high, for 5 minutes 
 
7. Second wash 
 
Dump supernatant 
 
just add 20mL of PBS and vortex 
 
Centrifuge: Spin at 1240 rpm (=364G), 4 Celsius, break high, for 5 minutes 
 
8. Count cells 
 
Dump supernatant 
 
add 1mL of PBS and vortex thoroughly 
 
take 10ul out and mix with 90ul of trypan blue 
 
count in hematocytometer  
 
9. Prepare freezing tubes and media 
 
Put cells in the meantime on ice 
 
Freezing media: FBS containing 10% DMSO 
 
1.8mL vials labeled with study #, time point, cell count, date, type of specimen, 
 
10. Final spin 
 
Add 20ml of PBS to the cells, vortex  
 
Centrifuge: Spin at 1240 rpm (=364G), 4°C, break high, for 5 minutes 
 
11. Freeze cells - General rules 
 
PBMCs: 1.5mL freezing media per 10 million cells (=1 vial) 
 
BMMCs: 1.5mL freezing media per 30 million cells (=1 vial) 
 
12. Freezing 
 
Put vials into Mr. Frosty® (container with Ethanol, that gradually cools down samples) and put into 
-80 Celsius fridge for about 24 hours 
 
After 24 hrs (up to 48hrs) transfer vials into liquid nitrogen tanks (to minimize temperature 
fluctuations make sure you transport them there on dry ice) 
 
Considerations regarding freezing and shipping 
 
 
Samples should optimally be processed the same day  
 
If there is a sample coming in late, keep it in the fridge (in 4◦C) overnight and process them early 
the next morning.  
Study # ____________ 
Pt ID#   ____________     
Timepoint: _________   
Cell count: __________ 
Date(time): _________ 
 
Blood or Marrow  

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 19 of 31 
 
Samples processed  should be stored in -80 Celsius for 24-48 hours and get transferred into liquid 
nitrogen thereafter 
 
If there are no liquid nitrogen tanks available, it’s permissible to keep samples in -80 Celsius for up 
to 2 weeks, but no longer.  
 
Important considerations: 
1. All work should be done using standard BSL2 procedures (blood and body fluid precautions). 
2. Maintain a clean workspace and use a containment laminar airflow hood when possible. 
3. Minimize the chance of contamination. 
4. Work quickly but methodically. 
5. Keep tubes closed as much as possible and work quickly. 
6. Change gloves frequently and maintain situational awareness 
8. RISKS 
8.1. IDELALISIB RISKS 
Known toxicities of idelalisib: idelalisib is FDA approved for the treatment of relapsed chronic lymphocytic 
leukemia/small lymphocytic lymphoma and follicular B-cell non-Hodgkin lymphoma. 
Idelalisib may cause: 
1. ALT/AST elevations and hyperbilirubinemia (most frequently occurs within the first 12 weeks of 
treatment); incidence of serious hepatotoxicity: 14.0% 
2. Diarrhea (mean time to occurrence 7.2 months); incidence of serious/severe diarrhea: 14.0% 
3. Pneumonitis; incidence <5% 
4. Neutropenia: Grade 3 or 4 neutropenia occurs in approximately 31% of patients receiving the 150mg 
bid dose.   
5. CYP3A affects: CYP3A inducers can reduce the AUC of idelalisib by 75%; CYP3A inhibitors can increase 
the AUC of idelalisib by 1.8 fold; idelalisib is strong CYP3A inhibitor. 
6. Increase risk of developing PCP 
7. CMV viremia 
 
8.2. RISK MINIMIZATION 
Patients will have comprehensive metabolic panels performed every 14 days through day +180 , then 
monthly through day +270.  
Patients undergoing allo BMT may develop intestinal aGVHD which may present with diarrhea or ileus.  All 
patients with >3 grade diarrhea will also be evaluated for aGVHD in addition to idelalisib dose modification. 
Patients undergoing allo BMT often develop late neutropenia after achieving neutrophil recovery.  To help 
limit the depth of neutropenia that could be attributable idelalisib, idelalisib will be dosed at 100mg bid, the 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 20 of 31 
suggested dose reduction for patients experiencing an ANC <.5Gi/L while on the standard 150mg bid dosing 
schedule 
CYP3A interactions.  Commonly, patients undergoing allo BMT require azole based antifungal prophylaxis 
and/or treatment.  Patients receiving posaconazole or voriconazole will have these levels checked every 14 days 
while receiving idelalisib.  
In the post allo BMT patient population, novel toxicities need to be considered: Non T-cell engraftment and 
acute GVHD.  Stopping rules, as defined in section 6.0 will be followed to stop this study, if compared to placebo 
l controls, the differential in incidence of toxicities of any kind between the idelalisib group and the placebo 
control  group is >10%.  
CMV viremia: CMV serum PCR analysis every 14 days between days 90-and day +120, then monthly through 
day +270: treat according to BMT policy guidelines. 
PCP: continue BMT policy guidelines of PCP primary prophylaxis for at least through the time of active-study 
participation.       
9. ADVERSE EVENTS 
9.1. 
OVERVIEW 
The Principal Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE (adverse event) or SAE (serious adverse event) as described in this protocol.  All AEs and 
SAEs will be recorded in the source documents and on the appropriate electronic CRF(s).  All data will be 
reviewed periodically by the SKCCC Safety Monitoring Committee (SMC), which may provide recommendations 
about withdrawing any participant and/or terminating the study because of safety concerns. 
Adverse events that are classified as serious according to the definition of health authorities must be 
reported promptly and appropriately to the Principal Investigators in the trial, IRBs and health authorities.  This 
section defines the types of AEs and outlines the procedures for appropriately collecting, grading, recording and 
reporting them.  Information in this section complies with 21CFR 312; ICH Guideline E2A: Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting; and ICH Guideline E-6: Guidelines for Good 
Clinical Practice; and applies the standards set forth in the National Cancer Institute (NCI), Common Terminology 
Criteria for Adverse Events, Version 4.0 (May 28, 2009). 
9.2. 
DEFINITIONS 
9.2.1 Adverse Events 
An AE is any occurrence or worsening of an undesirable or unintended sign, symptom, laboratory finding, 
or disease that occurs during participation in the trial.  An AE for participants will be followed until it resolves or 
until 30 days after the participant terminates from the study, whichever comes first. All AEs will be reported as 
specified in sections 9.2.2 and 9.2.3. Error! Reference source not found. Whether they are or are not related to 
disease progression or study participation. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 21 of 31 
9.2.2 Adverse Reaction and Suspected Adverse Reaction 
An adverse reaction means any adverse event caused by a drug.  Adverse reactions are a subset of all 
suspected adverse reactions for which there is reason to conclude that the drug caused the event. 
Suspected adverse reaction (SAR) means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of safety reporting, ‘reasonable possibility’ means 
there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected 
adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means 
any adverse event caused by a drug (21 CFR 312.32(a)). 
9.2.3 Serious Adverse Event or Serious Suspected Adverse Reaction 
An AE or SAR is considered “serious” if, in the view of the Investigator, it results in any of the following 
outcomes: 
 
Death: A death that occurs during the study or that comes to the attention of the Principal 
Investigator during the protocol-defined follow-up period as defined in  section 4.0 must be 
reported whether it is considered treatment-related or not. 
 
A life-threatening event: An AE or SAR is considered “life-threatening” if, in the view of the 
Investigator, its occurrence places the subject at immediate risk of death. It does not include an AE 
or SAR that, had it occurred in a more severe form, might have caused death.  
 
An event that requires intervention to prevent permanent impairment or damage.  An important 
medical event that may not result in death, be life threatening, or require hospitalization may be 
considered serious when, based upon appropriate medical judgment, it may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed 
above. 
9.2.4 Unexpected Adverse Events 
A SAR is considered “unexpected” if it is not identified in the package insert and/or drug label, or protocol, 
or is not listed at the specificity, or severity that has been observed (21 CFR 312.32(a)). 
9.3. 
COLLECTING AND RECORDING ADVERSE EVENTS 
9.3.1 Methods of Collection 
Adverse events for recipients will be collected from the time the participant receives the first dose of 
study medication as specified in section 9.4. Adverse events will be followed until the time an event is 
resolved or until 30 days after the recipient completes or terminates from the study, whichever comes first. 
The methods for collecting AEs will include:  
 
Observing the participant. 
 
Questioning the participant in an objective manner. 
 
Receiving an unsolicited complaint from the participant. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 22 of 31 
An abnormal value or result from a clinical or laboratory evaluation (e.g., a radiograph, an ultrasound, 
or an electrocardiogram) can also indicate an AE if it is determined by the Investigator to be clinically 
significant.  If this is the case, it must be recorded in the source document and as an AE on the appropriate 
AE form(s).  The evaluation that produced the value or result should be repeated until that value or result 
returns to normal or can be explained and the participant’s safety is not at risk. 
9.3.2 Severity of Adverse Events to be collected 
All AE grades will be defined per NCI-CTCAE version 4.0 criteria unless otherwise specified starting at the 
beginning of Idelalisib treatment 
With the following exceptions, all AEs of grade 3 or higher will be collected from the time at which the 
participant receives the first dose of study medication as specified in section 9.4until the time the participant 
completes or prematurely withdraws from the study: 
 
Haematological abnormalities will be collected as AEs per NCI-CTCAE v. 4.0 criteria once 
participants have achieved platelet and neutrophil recovery. 
 
All episodes of allograft failure and of acute, grade III or IV GVHD will be collected as AEs. 
 
9.4. 
GRADING AND ATTRIBUTION OF ADVERSE EVENTS 
 
9.4.1 Grading Criteria 
The study site will grade the severity of AEs experienced by study participants according to the criteria set 
forth in the National Cancer Institute’s Common Terminology Criteria for Adverse Events Version 
4.0 (published May 28, 2009).  This document (referred to herein as the “NCI-CTCAE v. 4.0 manual”) 
provides a common language to describe levels of severity, to analyze and interpret data, and to articulate 
the clinical significance of all AEs. 
Severity of adverse events will be graded on a scale from 1 to 5 according to the following standards in the 
NCI-CTCAE v. 4.0 manual: 
 
Grade 1 = mild adverse event. 
 
Grade 2 = moderate adverse event. 
 
Grade 3 = severe and undesirable adverse event.  
 
Grade 4 = life-threatening or disabling adverse event. 
 
Grade 5 = death. 
For additional information and a printable version of the NCI-CTCAE v. 4.0 manual, go to 
http://ctep.cancer.gov/reporting/ctc.html   
ATTRIBUTION DEFINITIONS 
Adverse events will be categorized for their relation to one or more of the following: 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 23 of 31 
 
bone marrow transplantation 
 
investigational study medication, Idelalisib  
 
other protocol-directed study procedures 
The Principal Investigator will do the initial determination of the relation, or attribution, of an AE 
to study participation and will record the initial determination on the appropriate eCRF and/or 
SAE reporting form.  The relation of an AE to study participation will be determined using 
definitions in Table 1.  
 
TABLE 1: ATTRIBUTION OF ADVERSE EVENTS 
Code 
Descriptor 
Relationship (to primary investigational product 
and/or other concurrent mandated study therapy) 
Unrelated Categories  
1 
Unrelated 
The adverse event is clearly not related. 
2 
Unlikely 
The adverse event is unlikely related. 
Related Categories 
3 
Possible 
The adverse event has a reasonable 
possibility to be related; there is evidence to 
suggest a causal relationship. 
4 
Probable 
The adverse event is likely related. 
5 
Definite 
The adverse event is clearly related. 
9.5. REPORTING SERIOUS ADVERSE EVENTS 
Serious adverse events must be reported to the Johns Hopkins University IRB within 48 hours of 
occurrence 
10. ETHICAL, REGULATORY, AND ADMINISTRATIVE CONSIDERATIONS 
10.1. 
STATEMENT OF COMPLIANCE 
This trial will be conducted in compliance with the protocol, current Good Clinical Practice (GCP) 
guidelines—adopting the principles of the Declaration of Helsinki—and all applicable regulatory requirements. 
Prior to study initiation, the protocol and the informed consent documents will be reviewed and approved 
by the sponsor and an appropriate ethics review committee or institutional review board (IRB).  Any 
amendments to the protocol or consent materials must also be approved by the Sponsor, the IRB and submitted 
to FDA before they are implemented. 
10.2. 
INFORMED CONSENT 
The principles of informed consent are described in the Code of Federal Regulations 21 CFR, part 50. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 24 of 31 
Participants or their legal guardians must be made aware of the investigational nature of this treatment 
protocol, and have the possible risks, hazards and benefits of the protocol explained to them.  The information 
that is given shall be in a language understandable to the participant.  No informed consent, whether oral or 
written, may include any exculpatory language through which the patient is made to waive or appear to waive 
any of their legal rights, or releases or appears to release the Principal Investigator, the institution, or its agents 
from liability for negligence. 
The participant, or legal guardian, must be able to comprehend the informed consent and must sign the 
document prior to registration on study. This will occur between Day +60 after HSCT and Day +100.  A copy of 
the informed consent will be given to a prospective participant for review.  The attending physician, in the 
presence of a witness, will review the consent and answer questions.  The participant will be informed that 
participation is voluntary and that he/she may withdraw from the study at any time, for any reason. The 
participant will receive a copy of the respective signed consent form. 
10.3. 
PRIVACY AND CONFIDENTIALITY  
A participant’s privacy and confidentiality will be respected throughout the study.  Each participant will be 
assigned a sequential identification number.  This number, rather than the participant’s name, will be used to 
collect, store, and report participant information. 
10.4. 
INSTITUTIONAL REVIEW 
The principles of Institutional Review Board (IRB) are described in the Code of Federal Regulations 21 CFR, 
part 56. 
The Principal Investigator will obtain approval for the study from the IRB. The Principal Investigator must 
notify the IRB within 5 days of protocol deviations in emergency situations regarding patient safety. The Principal 
Investigator will be responsible for obtaining annual IRB renewal through the duration of the study, or more 
frequently if required by the IRB.  Copies of the Principal Investigator's report and copies of the IRB’s 
continuance of approval must be maintained in the regulatory binder located at the clinical site. 
10.5. 
MONITORING PLAN 
This is a DSMP Level II study under the SKCCC Data Safety Monitoring Plan (12/6/2012). Data Monitoring of 
this protocol will occur on a regular basis with the frequency dependent on the rate of subject accrual and the 
progress of the study. The protocol will be monitored internally at SKCCC by the Principal Investigator and 
externally by the SKCCC CRO in accordance with SKCCC guidelines. Trial monitoring and reporting will be done 
through the Safety Monitoring Committee (SMC) at SKCCC. 
 
 
11. REFERENCES 
1. 
Chakrabarti S, Buyck HC. Reduced-intensity transplantation in the treatment of haematological 
malignancies: current status and future-prospects. Curr Stem Cell Res Ther 2007;2(2): 163-88. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 25 of 31 
2. 
Gill S, Porter DL. Reduced-intensity hematopoietic stem cell transplants for malignancies: 
harnessing the graft-versus-tumor effect. Annu Rev Med 2013;64: 101-17. 
3. 
Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell 
transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol 2007;19(6): 
660-6. 
4. 
Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE et al. Partially mismatched 
transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 
2013;19(4): 647-52. 
5. 
Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA et al. Post-transplantation 
cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched 
allografting for acute leukemias and myelodysplastic syndrome. Blood 2014. 
6. 
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone 
marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, 
posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6): 641-50. 
7. 
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. High-dose 
cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115(16): 
3224-30. 
8. 
Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic 
stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell 
transplantation: a GITMO study. Ann Hematol 2012;91(6): 931-9. 
9. 
Carpenter PA, Snyder DS, Flowers MED, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic 
administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-
positive leukemia. Blood 2007;109(7): 2791-2793. 
10. 
Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U. Current status and 
perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic 
myelogenous leukemia (CML). Biol Blood Marrow Transplant 2010;16(3): 301-10. 
11. 
Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M et al. Randomized 
comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell 
transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013;27(6): 1254-62. 
12. 
Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL et al. Response to tyrosine 
kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase 
following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16(5): 639-
46. 
13. 
Bolanos-Meade J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ et al. 5-azacytidine as salvage 
treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow 
Transplant 2011;17(5): 754-8. 
14. 
Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S et al. Effects of novel isoform-selective 
phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One 2014;9(6): e99486. 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 26 of 31 
15. 
Hirsch E, Novelli F. Cancer: natural-born killers unleashed. Nature 2014;510(7505): 342-3. 
16. 
Suarez-Fueyo A, Barber DF, Martinez-Ara J, Zea-Mendoza AC, Carrera AC. Enhanced 
phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers 
resistance to activation-induced T cell death. J Immunol 2011;187(5): 2376-85. 
17. 
Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL et al. Inactivation of PI(3)K p110delta 
breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510(7505): 407-11. 
18. 
Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B et al. Aldehyde 
dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. 
Sci Transl Med 2013;5(211): 211ra157. 
19. 
Warren EH, Matsen FAt, Chou J. High-throughput sequencing of B- and T-lymphocyte antigen 
receptors in hematology. Blood 2013;122(1): 19-22. 
20. Kanakry CG, Perkins SM, Daguindau E, et al. Plasma-Derived Proteomic Biomarkers Have Prognostic 
Utility in Patients Treated with Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host 
Disease Prophylaxis for HLA-Matched Allogeneic Bone Marrow Transplantation. ASBMT 2015: Abstract #486. 
21. Ramanathan, S., Jin, F., Sharma, S. et al.  Clin Pharmacokinet (2016) 55:33–45 DOI 10.1007/s40262-015-
0304-0 
22.   Wolach O, Bairey O, Lahav M. Late-Onset Neutropenia After Rituximab Treatment Case Series and 
Comprehensive Review of the Literature. Medicine 2010; 89(5): 308-318. 
 
 
 
 
 
 
 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 27 of 31 
12. APPENDIX 1-4 
 
Appendix 1:  Staging and grading of acute graft-versus-host disease 
1. Staging: Record the highest level of organ abnormalities during the assessment period: 
Use the “rule of 9s” to compute percentage of body surface area for the skin assessment. 
a. Skin 
      Stage I:   Maculopapular rash < 25% of body surface 
      Stage II:  Maculopapular rash 25-50% of body surface  
      Stage III:  Generalized erythroderma (>50% of body surface) 
Stage IV: Generalized erythroderma with bullous formations and desquamation 
b. Intestinal Tract 
       Stage I   > 500 ml/day  
             Stage II > 1000 ml/day  
             Stage III > 1500 ml/day  
             Stage IV > Severe abdominal pain, with or without ileus 
c. Liver 
       Stage I:   Bilirubin 2-3 mg/dL 
       Stage II:  Bilirubin 3-6 mg/dL 
       Stage III: Bilirubin 6-15 mg/dL 
       Stage IV: Bilirubin > 15 mg/dL 
 
2. Overall Clinical Grading of Severity of Acute GVHD: 
         Grade I: Stage 1-2 skin rash; no gut involvement; no liver involvement; no decrease in 
clinical performance 
Grade II: Stage 1-3 rash; stage 1 gut involvement, or stage 1 liver involvement (or both); 
mild decrease in clinical performance 
Grade III-Stage 2-3 skin rash; 2-3 gut involvement or stage 2-4 liver involvement (or 
both); marked decrease in clinical performance 
Grade IV-Similar to Grade III with stage 2-4 organ involvement and extreme decrease in 
clinical performance 
 
 
 
 
 
 
 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 28 of 31 
Appendix 2: Study Calendar and Schema 
 
12.1. 
STUDY CALENDAR 
 
Screening and 
Baseline  
( 
Cycle 1, Day 1 
Day +90 (± 10 
Days) 
Cycle 1, Day 15 
Cycles 2-6 
Day 1 
(+/- 7 days) 
30 days 
Post last 
dose 
Month 12 
(± 14 Days) 
Informed Consenta 
Days 60 -100 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
Physical Exam 
X 
X 
 
X 
X 
X 
AE Assessment 
X 
X 
 
X 
X 
X 
CBC with diff  
X 
X 
X 
X 
X 
X 
Comprehensive 
metabolic panel e 
(CMP) b 
Xb 
Xb 
Xb 
Xb 
Xb 
Xb 
PT, PTT, INR 
X 
 
 
 
 
 
Serum -HCG (if 
applicable) 
X 
 
 
 
 
 
CMV PCRd 
Xd 
X 
X 
X 
 
 
Idelalisib 
 
X 
 
X 
 
 
Standard of care per 
institution 
 
 
 
 
 
 
T-cell chimerism 
X 
 
 
 
 
X 
Bone marrow biopsy 
(as std of care) 
X 
 
 
 
 
X 
aGVHD/cGVHD 
assessments 
X 
X 
X 
X 
 
X 
Correlative studiesc 
X 
X 
 
Xc 
 
X 
 
 
 
 
 
 
 
aInformed consent will be collected beginning on Day +60 after BMT until Day +100. 
b CMP to include BUN, creatinine, sodium, potassium, chloride, AST, ALT, total bilirubin, alkaline phosphatase.  
c Additionally specimens should be obtained from peripheral blood and bone marrow collections as a part of routine clinical 
care such as GVHD, toxicity and/or disease relapse Correlative peripheral blood samples should be collected on Day 1 of every 
other cycle beginning with Cycle 2 
dCytomegalovirus (CMV) viral load assay will be monitored by PCR every 14 days between days +90-and day +120, then monthly 
through day +270: treat according to BMT policy guidelines.  
 
 
 
 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 29 of 31 
Appendix 3:  Performance Status Scales 
  
 ECOG PERFORMANCE STATUS SCALE GRADE DESCRIPTION 
 
0 Fully active, able to carry on all pre-disease activities without restriction. 
1 Restricted in physically strenuous activities and able to carry out work of a light or sedentary 
nature, e.g. light housework, office work. 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours. 
3 Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
5 Dead. 
 
 
KARNOFSKY PERFORMANCE STATUS SCALE 
 
100 
Normal no complaints; no evidence of disease 
90 
Able to carry on normal activity; minor signs or symptoms of disease. 
Able to carry on normal activity and to work; no special care needed. 
80 
Normal activity with effort; some signs or symptoms of disease. 
70 
Cares for self; unable to carry on normal activity or to do active work. 
60 
Requires occasional assistance, but is able to care for most of his personal needs. Unable to work; 
able to live at home and care for most personal needs; varying amount ofassistance needed. 
50 
Requires considerable assistance and frequent medical care. 
40 
Disabled; requires special care and assistance. 
30 
Severely disabled; hospital admission is indicated although death not imminent. 
20 
Very sick; hospital admission necessary; active supportive treatment necessary. 
10 
Moribund; fatal processes progressing rapidly. Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be progressing rapidly. 
0 
Dead 
 
 
 
 
 
 
 
 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 30 of 31 
Appendix 4: Counterindicated Medications 
CYP3A affects: CYP3A inducers can reduce the AUC of idelalisib by 75%; CYP3A inhibitors can increase the AUC of 
idelalisib by 1.8 fold; idelalisib is strong CYP3A inhibitor. Importantly, with direct relevance to this study is the lack 
of data supporting strong interaction with voriconazole.  Azoles are often the medication of choice for patients with 
suspect fungal or anti-bacterial non-responsive fevers during alloBMT.  The elimination of idelalisib is predominantly 
mediated by the hepatic pathway.  Idelalisib is primarily metabolized by aldehyde oxidase with a lesser involvement 
of cytochrome P450.  The major metabolite of idelalisib is GS-563117.  Data indicate that CYP3A inhibition by 
concurrent use of azoles may result in modestly higher exposures of idelalisib, but the change is not of clinical 
relevance21. In this study, as the dosing of idelalisib is already reduced to 100mg bid to provide additional risk 
mitigation.  Additionally, patient’s receiving azole therapy while on idelalisib will have serum levels monitored to 
adjust to target levels 
List of prohibited inhibitors and inducers of isoenzyme CYP3A 
INDUCERS 
Strong inducers: 
avasimibe, carbamazepine, mitotane, phenobarbital, phenytoin, rifabutin, rifampin  
(rifampicin), St. John's wort (hypericum perforatum) 
 
Moderate inducers: 
bosentan, efavirenz, etravirine, genistein, modafinil, nafcillin, ritonavir, 
[talviraline], thioridazine, tipranavir 
 
Weak inducers: 
amprenavir, aprepitant, armodafinil (R-modafinil), bexarotene, clobazam, danshen,  
dexamethasone, Echinacea, garlic (allium sativum), gingko (ginkgo biloba),  
glycyrrhizin, methylprednisolone, nevirapine, oxcarbazepine, pioglitazone,  
prednisone, [pleconaril], primidone, raltegravir, rufinamide, sorafenib, telaprevir,  
terbinafine, topiramate, [troglitazone] , vinblastine 
INHIBITORS 
Strong Inhibitors: 
 Boceprevir,clarithromycin, conivaptan,grapefruit juice, indinavir, itraconazole, 
ketoconazole, lopinavir/ritonavir,mibefradil, nefazodone, nelfinavir,posaconazole, 
ritonavir, saquinavir, telaprevir,telithromycin,voriconazole  
Moderate inhibitors: 
Amprenavir, aprepitant,atazanavir, ciprofloxacin,darunavir/ritonavir, diltiazem, 
erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil 
 
Weak inhibitors: 
Alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, 
cimetidine, 

Johns Hopkins Protocol ID: J1633 
IND: 131805 
Version Date: February 3, 2020  
 
Page 31 of 31 
cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal,isoniazid, nilotinib,oral 
contraceptives, ranitidine, ranolazine, tipranavir/ritonavir, zileuton 
 
 
CLINICALLY RELEVANT DRUG INTERACTIONS MEDIATED BY PGP 
PgP Substrates 
PgP Inhibitors and 
PgP/CYP3A Dual 
Inhibitors 
PgP Inducers 
digoxin, fexofenadine,  
indinavir, vincristine, 
colchicine, topotecan, 
paclitaxel, talinolol, 
everolimus 
amiodarone, 
azithromycin, captopril, 
carvedilol, clarithromycin, 
conivaptan, diltiazem, 
dronedarone, elacridar, 
erythromycin, felodipine, 
(GF120918), fexofenadine, 
fluvoxamine, ginko (ginko 
biloba), indinavir, 
itraconazole, lopinavir, 
(LY335979), mibefradil, 
milk thistle (silybum 
marianum), nelfinavir,  
nifedipine, nitrendipine, 
(PSC833), paroxetine, 
quercetin, quinidine, 
ranolazine, rifampin, 
ritonavir, saquinavir, 
Schisandra chinesis, St 
John’s wort (hypericum 
perforatum),  talinolol, 
Telaprevir, telmisartan, 
ticagrelor, tipranavir, 
tolvaptan valspodar, 
verapamil 
rifampin,                       St 
John’s wort